Anaphylactic reaction due to zomepirac

Area of Science:

• Pharmacology
• Clinical Toxicology

Background:

• Zomepirac sodium is a nonsteroidal anti-inflammatory drug (NSAID) known for its strong analgesic effects.
• Initially, it was considered well-tolerated with minimal toxicity.
• Prostaglandin inhibition is its primary mechanism of action.

Observation:

• The first reported case of anaphylaxis linked to zomepirac sodium occurred in April 1981.
• A total of seven cases of anaphylaxis have been documented in the literature.
• The manufacturer voluntarily withdrew zomepirac sodium from the market in March 1983.

Findings:

• This report details an additional case of anaphylactic reaction to zomepirac sodium.
• A review of existing literature on zomepirac-associated anaphylaxis is included.

Implications:

• The findings highlight the potential for severe hypersensitivity reactions to zomepirac sodium.
• The study underscores the importance of post-marketing surveillance for drug safety.
• Further investigation into the immunogenic properties of zomepirac sodium is warranted.